(+/-)-3-CARBAMOYLMETHYL-5METHYLHEXANOIC ACID (CMH)

(+/-)-3-Carbamoylmethyl-5-methylhexanoic acid (CMH) is a key intermediate used in the synthesis of Pregabalin, a widely prescribed medication for epilepsy, neuropathic pain, and anxiety disorders. CMH is a racemic compound, meaning it contains both the (R)- and (S)-enantiomers in equal proportions. However, only the (S)-enantiomer is pharmacologically active and is used in the final formulation of Pregabalin. In industrial manufacturing, CMH is synthesized first and then subjected to chiral resolution or asymmetric synthesis to isolate the active (S)-form. This intermediate plays a critical role in ensuring the stereochemical purity and therapeutic efficacy of the final API. Although CMH itself is not an active drug, its quality and enantiomeric purity are essential for the production of Pregabalin that meets international pharmacopeial standards.